Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans.
BACKGROUND
Reporting further developments evolved since the first report about this conformal technique.


METHODS
Technical progress focused on optimization of the quality assurance (QA) program, especially regarding the required work input; and on optimization of beam arrangements.


RESULTS
Besides performing the regular QA program, additional time consuming dosimetric measurements and verifications no longer have to be accomplished.'Class solutions' of treatment plans for six patients with non-resected non-small cell lung cancer in locally advanced stages are presented. Target configurations comprise one central and five peripheral tumor sites with different topographic positions to hilus and mediastinum. The mean dose to the primary tumor is 81,9 Gy (range 79,2-90,0 Gy), to macroscopically involved nodes 61,2 Gy (range 55,8-63,0 Gy), to electively treated nodes 45,0 Gy. Treatments are performed twice daily, with fractional doses of 1,8 Gy at an interval of 11 hours. Median overall treatment time is 33 days. The set-up time at the linac does not exceed the average time for any other patient.


CONCLUSIONS
Target splitting is a highly conformal and nonetheless non-expensive method with regard to linac and staff time. It enables secure accelerated high-dose treatments of patients with NSCLC.
Wurstbauer
Karl
K
Department of Radiation Oncology and radART - Institute for Research and Development on Advanced Radiation Technologies at the Paracelsus Medical University, Salzburg, Austria. k.wurstbauer@salk.at
Deutschmann
Heinz
H
Kopp
Peter
P
Merz
Florian
F
Schöller
Helmut
H
Sedlmayer
Felix
F
D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D020266:Radiotherapy, Conformal / Q000379:methods*
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33
16168827
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1015-24
11072158
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):453-63
12023150
Radiother Oncol. 2005 May;75(2):165-70
16086907
Med Phys. 2008 Jan;35(1):310-7
18293586
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28
15667949
Front Radiat Ther Oncol. 1996;29:199-206
8742900
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):741-7
15465190
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):809-13
7790268
J Thorac Oncol. 2008 Aug;3(8):819-31
18670299
Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):111-6
106031
J Clin Oncol. 2007 Dec 10;25(35):5557-61
17984185
Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):993-1000
7493861
Acta Oncol. 2001;40(6):712-7
11765065
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):333-41
10760428
Radiother Oncol. 1997 Jul;44(1):17-22
9288852
Strahlenther Onkol. 2008 Feb;184(2):93-9
18259701
Radiother Oncol. 1999 Aug;52(2):137-48
10577699
Strahlenther Onkol. 2007 Dec;183 Spec No 2:38-40
18167008